BiotechTube

ALIMTA + gemcitabine

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urologic Neoplasms

Conditions

Urologic Neoplasms

Trial Timeline

— → —

NCT ID
NCT00034593

About ALIMTA + gemcitabine

ALIMTA + gemcitabine is a phase 2 stage product being developed by Eli Lilly for Urologic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00034593. Target conditions include Urologic Neoplasms.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00034593Phase 2Completed

Competing Products

16 competing products in Urologic Neoplasms

See all competitors
ProductCompanyStageHype Score
pemetrexed + cisplatinEli LillyPhase 1/2
41
Mirabegron + Solifenacin succinate + PlaceboAstellas PharmaPhase 2
52
Mirabegron + Solifenacin succinateAstellas PharmaPhase 3
77
GemcitabineEli LillyPhase 2
52
pemetrexedEli LillyPhase 2
52
BBI503Sumitomo PharmaPhase 2
52
Pembrolizumab Injection [Keytruda]MerckPhase 2
52
Carboplatin/Paclitaxel + PembrolizumabMerckPhase 2
52
zoledronic acidNovartisPhase 2
52
mycophenolate mofetilRochePhase 1
33
Cetuximab + PaclitaxelBristol Myers SquibbPhase 2
51
Nivolumab + RelatlimabBristol Myers SquibbPhase 2
51
CBT101 + PlaceboBrain BiotechPhase 1
25
OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + CarboplatinAchieve Life SciencesPhase 2
44
S-8184 Paclitaxel Injectable Emulsion + Experimental Arm: TOCOSOL PaclitaxelAchieve Life SciencesPhase 2
44
Stem CellBrain BiotechPhase 1
25

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85